Use as an adjunct to diet and other low-density lipoprotein cholesterol
lowering therapies for the treatment of adult and adolescent patients aged ≥12
years with homozygous familial hypercholesterolaemia. Await clinician request
Do Not Prescribe (DNP) Drug Classifications
2: Have a lack of data on safety compared with standard therapy
4: Have a lack of data on cost-effectiveness compared with standard therapy
5: Less cost-effective than current standard therapy
